DEXMEDETOMIDINE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEXMEDETOMIDINE HYDROCHLORIDE (DEXMEDETOMIDINE HYDROCHLORIDE).
Selective alpha-2 adrenergic receptor agonist in the brainstem, resulting in decreased sympathetic outflow, sedation, and analgesia.
| Metabolism | Extensively metabolized in the liver via glucuronidation and N-methylation; CYP2A6 involved in minor pathway. |
| Excretion | Renal (95% as metabolites, <1% unchanged); fecal (4%). |
| Half-life | Terminal elimination half-life is approximately 2 hours. In critically ill patients, the half-life may be prolonged (up to 6-7 hours) due to reduced clearance. |
| Protein binding | About 94% bound to serum albumin and alpha1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 2-3 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Bioavailability by oral route is low (approximately 16%) due to extensive first-pass metabolism. Buccal/sublingual: approximately 65-82%. Intramuscular: not approved; no data. Intravenous: 100%. |
| Onset of Action | Intravenous: Sedative effect within 5-10 minutes (bolus); analgesic effect within 5-10 minutes. Intramuscular: Not approved; no data. |
| Duration of Action | Intravenous bolus: Approximately 30-60 minutes for sedative effect; with continuous infusion, effects persist for 1-2 hours after discontinuation. Clinical context: used for short-term sedation in ICU. |
Loading dose: 1 mcg/kg IV over 10 minutes. Maintenance infusion: 0.2-0.7 mcg/kg/hour IV, titrate to effect. Max dose: 1 mcg/kg/hour.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment (including ESRD). |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce maintenance infusion to 0.15-0.5 mcg/kg/hour. Child-Pugh C: Not recommended. |
| Pediatric use | Children ≥1 month: Loading dose: 1 mcg/kg IV over 10 minutes; maintenance: 0.2-1 mcg/kg/hour IV, titrate to desired sedation level. |
| Geriatric use | Elderly patients (≥65 years): Reduce loading dose to 0.5 mcg/kg IV over 10 minutes. Maintenance infusion: 0.2-0.5 mcg/kg/hour; use lower initial doses and titrate cautiously due to increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DEXMEDETOMIDINE HYDROCHLORIDE (DEXMEDETOMIDINE HYDROCHLORIDE).
| Breastfeeding | Excreted in rat milk; human data absent. M/P ratio unknown. Use with caution; monitor infant for sedation and bradycardia. |
| Teratogenic Risk | Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Potential for fetal bradycardia or hypotension, especially with prolonged use or high doses. Risk may be increased in third trimester due to placental transfer. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning exists for dexmedetomidine.
| Serious Effects |
["Hypersensitivity to dexmedetomidine or any component of the formulation.","Recent administration of haloperidol or other drugs that prolong QT interval (relative)."]
| Precautions | ["Hypotension and bradycardia may occur; monitor vital signs.","Rebound hypertension upon abrupt discontinuation.","Potential for withdrawal symptoms with prolonged use.","Not recommended for use beyond 24 hours for procedural sedation.","Use caution in patients with advanced heart block, bradycardia, or hypotension."] |
Loading safety data…
| Continuous maternal heart rate, blood pressure, oxygen saturation; fetal heart rate monitoring during labor. Assess for maternal hypotension, bradycardia, and sedation. |
| Fertility Effects | No human studies on fertility. Animal studies show no adverse effects on fertility at recommended doses. |